Vaccines, Vaccination and Immunization

About Conference

The 8^th International Conference on Vaccines, Vaccination and Immunization will be held on July 27–28, 2027, in Paris, France, bringing together leading researchers, healthcare professionals, immunologists, epidemiologists, public health experts, vaccine developers, pharmaceutical professionals, policymakers, and industry representatives from around the world.

Conference Theme: “Advancing Vaccine Innovation and Immunization Strategies for a Healthier Global Future”

The conference will focus on vaccine research, development, clinical applications, immunization programmes, emerging vaccine technologies, vaccine safety, infectious-disease prevention, public-health strategies, and global access to vaccination. It will also provide an international platform for sharing research findings, clinical experiences, innovative technologies, and strategies for strengthening vaccination programmes.

The conference is particularly relevant as global immunization programmes continue to face challenges involving coverage gaps, unequal access, vaccine confidence, disease outbreaks, financing, supply, and the introduction of new vaccines. WHO reported that in 2025, 85% of infants globally received three doses of DTP-containing vaccine, while 13.5 million children remained zero-dose children.

Why Attend?

• Explore the latest developments in vaccine research and immunology.
• Learn about emerging vaccine platforms and next-generation technologies.
• Discuss strategies for improving global vaccination coverage.
• Understand advances in vaccine safety, efficacy, and clinical evaluation.
• Exchange knowledge on infectious-disease prevention and outbreak preparedness.
• Discover approaches to addressing vaccine hesitancy and confidence.
• Discuss vaccine manufacturing, quality control, supply chains, and accessibility.
• Explore opportunities for collaboration between academia, healthcare, government, and industry.
• Present research through oral presentations, posters, workshops, and scientific sessions.
• Build professional and research networks with international experts.
• Examine progress toward the goals of the Immunization Agenda 2030 (IA2030), which aims to ensure that people everywhere benefit from vaccines throughout the life course.

Target Audience

The conference welcomes:

• Vaccine Researchers and Scientists
• Immunologists
• Microbiologists
• Virologists
• Epidemiologists
• Infectious Disease Specialists
• Pediatricians
• Physicians and Clinicians
• Public Health Professionals
• Nurses and Healthcare Practitioners
• Pharmacists
• Biotechnologists
• Vaccine Developers
• Clinical Researchers
• Pharmaceutical Industry Professionals
• Vaccine Manufacturing Professionals 

Sessions/Tracks

1. Advances in Vaccine Research and Development

This session will explore the latest advances in vaccine research, discovery, and development. It will cover innovative approaches for identifying vaccine targets, improving antigen design, enhancing immune responses, and developing vaccines against established and emerging infectious diseases. Researchers will have the opportunity to present findings from laboratory studies, preclinical research, and translational vaccine programmes. Discussions will also address challenges involved in moving promising vaccine candidates from research laboratories into clinical development. The session will highlight interdisciplinary collaboration among immunologists, microbiologists, molecular biologists, clinicians, pharmaceutical companies, and biotechnology organizations. Participants will gain insights into current research directions, emerging scientific approaches, and opportunities for accelerating the development of safe, effective, scalable, and accessible vaccines for diverse populations worldwide.

2. Next-Generation Vaccine Technologies

This session will focus on innovative vaccine platforms that are transforming modern vaccinology. Topics will include recombinant vaccines, viral-vector platforms, nanoparticle-based vaccines, self-amplifying RNA technologies, thermostable formulations, and other emerging approaches. Speakers will discuss how next-generation technologies may improve vaccine development speed, production scalability, stability, and immune responses. The session will also examine technological challenges, manufacturing considerations, regulatory requirements, and clinical translation. Researchers and industry professionals can share experiences from vaccine development programmes and discuss opportunities for applying emerging technologies to infectious diseases and other health conditions. The session will provide a multidisciplinary platform for understanding how advances in biotechnology, molecular engineering, immunology, and pharmaceutical sciences are contributing to the development of innovative vaccination solutions.

3. mRNA and Nucleic Acid Vaccines

This session will examine developments in mRNA, DNA, and other nucleic-acid vaccine technologies. Discussions will cover antigen design, delivery systems, lipid nanoparticles, formulation technologies, immune responses, manufacturing, and clinical development. Researchers will present emerging findings on the application of nucleic-acid platforms to infectious diseases and other potential indications. Particular attention will be given to opportunities for rapid vaccine design and adaptation in response to emerging pathogens. Speakers may also address challenges related to stability, storage, manufacturing capacity, regulatory evaluation, and global accessibility. The session will bring together molecular biologists, immunologists, vaccine developers, clinicians, biotechnology researchers, and pharmaceutical professionals to exchange knowledge about the evolving role of nucleic-acid technologies in modern vaccine research and future immunization strategies.

4. Vaccine Immunology and Immune Responses

This session will explore the biological mechanisms underlying vaccine-induced immunity and protection. Topics will include innate and adaptive immune responses, antibody production, T-cell responses, immune memory, mucosal immunity, adjuvants, and factors influencing individual responses to vaccination. Researchers will discuss how age, previous infection, genetics, underlying conditions, and vaccination schedules can influence immune responses. The session will also examine approaches for improving vaccine immunogenicity and developing vaccines capable of generating durable protection. Presentations may include laboratory, translational, and clinical research findings. By bringing together immunologists, microbiologists, clinicians, and vaccine researchers, this session will provide an opportunity to understand the scientific principles behind effective vaccination and explore emerging strategies for improving immune protection against infectious diseases.

5. Vaccine Clinical Trials and Evaluation

This session will focus on the clinical evaluation of vaccine candidates from early-stage studies through large-scale clinical trials and post-authorization assessment. Topics will include trial design, participant recruitment, endpoints, immunogenicity, efficacy, effectiveness, safety monitoring, and statistical evaluation. Researchers will discuss lessons from clinical development programmes and approaches for generating reliable evidence for vaccine decision-making. The session will also examine challenges associated with conducting trials across different populations, geographical regions, and healthcare settings. Discussions may cover adaptive trial designs, real-world evidence, post-marketing studies, and long-term monitoring. The session will provide a valuable platform for clinical researchers, epidemiologists, regulatory professionals, pharmaceutical companies, and healthcare experts to exchange knowledge about advancing vaccine candidates through evidence-based clinical development.

6. Vaccine Safety, Pharmacovigilance and Adverse Events

This session will address vaccine safety throughout the development and post-licensure stages. Topics will include adverse-event monitoring, pharmacovigilance systems, safety signal detection, risk assessment, benefit-risk evaluation, and post-marketing surveillance. Experts will discuss approaches for identifying and investigating potential safety concerns while maintaining public confidence in vaccination programmes. The session will also consider methods for strengthening safety monitoring systems and improving communication about vaccine safety findings. Researchers may present data from clinical studies, national surveillance programmes, and real-world vaccination settings. The session is designed for pharmacovigilance professionals, clinicians, epidemiologists, regulators, researchers, public-health specialists, and pharmaceutical representatives interested in understanding current approaches to monitoring vaccine safety and strengthening evidence-based vaccine safety systems.

7. Childhood Vaccination and Routine Immunization

This session will focus on childhood vaccination and strategies for strengthening routine immunization programmes. Discussions will cover vaccination schedules, coverage improvement, missed and delayed vaccinations, catch-up programmes, community-based services, and approaches for reaching children who remain unvaccinated. Participants will examine challenges affecting routine childhood immunization, including healthcare access, supply constraints, geographical barriers, misinformation, and service disruptions. Researchers and public-health professionals will share evidence and practical experiences from different settings. The session will also consider methods for improving monitoring, identifying underserved populations, and integrating vaccination services with broader child-health programmes. It will provide a platform for pediatricians, nurses, public-health professionals, immunization managers, researchers, and policymakers to exchange strategies for improving childhood vaccination coverage and protecting children from vaccine-preventable diseases.

8. Maternal, Neonatal and Adolescent Immunization

This session will explore vaccination strategies across pregnancy, infancy, childhood, and adolescence. Topics will include maternal immunization, protection of newborns through maternal antibodies, neonatal vaccination research, adolescent vaccination programmes, and strategies for improving vaccine uptake among young people. Speakers may discuss vaccines recommended during pregnancy, safety considerations, immunization schedules, and approaches for integrating vaccination with maternal and reproductive healthcare. Adolescent immunization topics may include HPV vaccination and other age-appropriate vaccines. The session will highlight the importance of life-course immunization and coordinated healthcare services. It will bring together obstetricians, pediatricians, immunologists, public-health professionals, nurses, researchers, and policymakers to discuss evidence-based approaches for improving vaccination access and protection among mothers, newborns, children, and adolescents.

9. Adult and Healthy Aging Vaccination

This session will examine the growing importance of vaccination throughout adulthood and older age. Discussions will address adult immunization schedules, vaccination among healthcare workers and other occupational groups, travel vaccination, and immunization of older adults. Speakers may explore vaccination against influenza, pneumococcal disease, respiratory infections, shingles, and other vaccine-preventable conditions. The session will also consider factors that influence vaccine uptake among adults, including awareness, access, healthcare-provider recommendations, and confidence. Researchers can present evidence on vaccine effectiveness and immune responses in aging populations. The session will provide a multidisciplinary platform for physicians, geriatric specialists, pharmacists, nurses, epidemiologists, public-health professionals, and researchers to discuss strategies for strengthening life-course immunization and supporting healthier aging through vaccination.

10. HPV Vaccination and Cancer Prevention

This session will focus on the role of HPV vaccination in preventing HPV-related cancers and improving long-term public health outcomes. Topics will include vaccine effectiveness, vaccination schedules, adolescent immunization, population coverage, cervical cancer prevention, and strategies for reaching underserved communities. Experts may discuss approaches for integrating HPV vaccination with screening and other cancer-prevention programmes. The session will also examine factors influencing vaccine acceptance, communication strategies, and opportunities to improve vaccination uptake among eligible populations. Researchers can present epidemiological studies, clinical research, implementation experiences, and public-health initiatives. The session will bring together oncologists, gynecologists, epidemiologists, immunologists, pediatricians, public-health specialists, and researchers to exchange knowledge about expanding HPV vaccination and strengthening comprehensive strategies for preventing HPV-associated diseases.

11. Influenza, RSV and Respiratory Virus Vaccines

This session will examine vaccine research and immunization strategies targeting influenza, respiratory syncytial virus (RSV), COVID-19, and other respiratory pathogens. Discussions will cover vaccine development, antigenic variation, immune responses, effectiveness, seasonal vaccination, booster strategies, and vaccination of vulnerable populations. Researchers may present findings from clinical trials, surveillance studies, and real-world vaccine programmes. The session will also consider challenges associated with rapidly changing respiratory viruses and the need for adaptable vaccine technologies. Speakers will discuss strategies for improving vaccination coverage among children, older adults, healthcare workers, and individuals at increased risk of severe disease. The session provides an opportunity for virologists, immunologists, clinicians, epidemiologists, vaccine developers, and public-health professionals to exchange knowledge on respiratory virus prevention.

12. Emerging and Neglected Disease Vaccines

This session will explore vaccine development for emerging, re-emerging, and neglected infectious diseases. Topics may include malaria, tuberculosis, dengue, chikungunya, cholera, Ebola, Zika, and other diseases affecting global health. Researchers will discuss antigen discovery, vaccine platforms, clinical development, disease surveillance, and strategies for introducing vaccines into affected populations. Particular attention will be given to diseases where scientific, economic, geographical, or healthcare-system challenges have historically limited vaccine development or access. Speakers may present new research findings, clinical experiences, and implementation strategies. The session will encourage collaboration among infectious-disease specialists, microbiologists, epidemiologists, immunologists, vaccine developers, public-health experts, and global-health organizations working to expand vaccine options for diseases that continue to affect vulnerable communities worldwide.

13. Global Immunization Programmes and Public Health

This session will examine the role of immunization programmes in protecting populations and reducing the burden of vaccine-preventable diseases. Discussions will cover national vaccination programmes, international immunization initiatives, disease elimination strategies, vaccination coverage monitoring, programme implementation, and health-system integration. Experts will share experiences from different countries and healthcare settings, highlighting approaches for improving programme performance and reaching underserved populations. The session will also consider the importance of surveillance, data systems, workforce capacity, financing, and community engagement. Researchers and public-health professionals can present programme evaluations and implementation research. The session will provide a platform for policymakers, epidemiologists, immunization managers, healthcare professionals, researchers, and global-health organizations to exchange practical knowledge on strengthening sustainable and equitable immunization programmes.

14. Vaccine Hesitancy, Confidence and Public Communication

This session will explore factors influencing public attitudes toward vaccination and strategies for strengthening vaccine confidence. Discussions will examine communication approaches, community engagement, misinformation, social and behavioral factors, healthcare-provider communication, and trust in health systems. Researchers will present evidence on interventions designed to improve vaccine acceptance and address concerns within different communities. The session will also examine the importance of transparent communication about vaccine benefits, limitations, safety monitoring, and uncertainty. Speakers may discuss digital communication, social media, community leaders, and culturally appropriate approaches to vaccination messaging. The session will bring together behavioral scientists, public-health professionals, communication specialists, clinicians, researchers, and policymakers to exchange evidence-based approaches for supporting informed vaccination decisions and improving participation in immunization programmes.

15. Vaccine Equity, Access and Global Health

This session will address differences in access to vaccines across countries, communities, and population groups. Topics will include affordability, availability, distribution, healthcare infrastructure, financing, zero-dose populations, geographic barriers, and strategies for reaching underserved communities. Speakers will examine approaches for improving equitable access to routine and newly introduced vaccines, particularly in low- and middle-income settings. Discussions may also cover international partnerships, procurement systems, technology transfer, local manufacturing, and sustainable immunization financing. Researchers and global-health professionals can present evidence from vaccination programmes and access initiatives. The session will encourage dialogue among public-health experts, policymakers, researchers, healthcare organizations, NGOs, vaccine manufacturers, and international institutions working toward broader and more equitable access to safe and effective vaccines.

16. Vaccine Manufacturing, Quality Control and Scale-Up

This session will explore the scientific, technological, and operational aspects of vaccine manufacturing. Topics will include production platforms, process development, formulation, quality control, quality assurance, validation, technology transfer, manufacturing capacity, and large-scale production. Experts from pharmaceutical and biotechnology organizations can discuss approaches for improving efficiency, consistency, scalability, and product quality. The session will also examine challenges associated with expanding manufacturing capacity during public-health emergencies and strengthening regional vaccine production. Researchers may present innovations in bioprocessing, analytical methods, automation, and manufacturing technologies. The session will provide opportunities for collaboration among vaccine manufacturers, biotechnology companies, pharmaceutical professionals, quality specialists, engineers, researchers, and regulatory experts working to strengthen vaccine production and supply capabilities.

17. Cold Chain, Storage and Vaccine Delivery Systems

This session will focus on the systems required to safely store, transport, and deliver vaccines from manufacturers to vaccination sites. Topics will include temperature monitoring, cold-chain infrastructure, transportation, storage technologies, last-mile delivery, inventory management, and innovative distribution systems. Experts will discuss challenges associated with maintaining vaccine quality in remote and resource-limited settings. The session may also examine new approaches such as temperature-stable formulations, digital monitoring technologies, solar-powered refrigeration, and improved logistics systems. Researchers and programme managers can share practical experiences and implementation findings. The session will bring together supply-chain specialists, immunization managers, public-health professionals, engineers, logistics companies, vaccine manufacturers, and healthcare organizations to discuss approaches for strengthening reliable and efficient vaccine delivery systems.

18. Regulatory Affairs and Vaccine Policy

This session will examine regulatory science, vaccine authorization, policy development, and post-approval oversight. Discussions will cover regulatory pathways, quality requirements, clinical evidence, benefit-risk assessment, licensing, manufacturing standards, and post-marketing monitoring. Experts will discuss how regulatory authorities evaluate vaccine quality, safety, and effectiveness before and after authorization. The session may also address international regulatory collaboration, harmonization, emergency-use pathways, and policy decisions surrounding vaccine introduction. Researchers, pharmaceutical companies, regulatory professionals, clinicians, and policymakers can share experiences and perspectives on navigating complex vaccine-development requirements. The session will provide an opportunity to understand the evolving regulatory environment and explore approaches that support timely access to safe, effective, high-quality vaccines while maintaining appropriate scientific and regulatory standards.

19. Artificial Intelligence, Digital Health and Vaccine Innovation

This session will explore the growing role of artificial intelligence, data science, and digital technologies in vaccine research and immunization programmes. Topics will include AI-assisted antigen discovery, computational vaccine design, predictive modelling, clinical-trial optimization, disease surveillance, digital vaccination records, and immunization data analytics. Speakers may discuss how digital tools can support programme monitoring, identify vaccination gaps, improve supply management, and assist research decision-making. The session will also consider data quality, privacy, validation, ethics, and responsible use of AI in healthcare. Researchers, data scientists, immunologists, clinicians, digital-health professionals, biotechnology companies, and public-health experts will have opportunities to share innovative applications and discuss how emerging technologies may contribute to more efficient vaccine development and immunization systems.

20. Future of Vaccines and Pandemic Preparedness

This session will examine future directions in vaccine science and strategies for preparing for emerging infectious-disease threats. Discussions will include rapid vaccine-development platforms, prototype pathogen research, genomic surveillance, pandemic preparedness, outbreak response, manufacturing readiness, global collaboration, and vaccine distribution. Experts will explore lessons from recent public-health emergencies and consider approaches for improving the speed and resilience of future vaccine responses. The session may also address investment in research infrastructure, regulatory preparedness, workforce development, and international cooperation. Researchers, clinicians, epidemiologists, vaccine developers, policymakers, pharmaceutical professionals, and global-health organizations will come together to discuss emerging priorities and innovative approaches for strengthening global preparedness and ensuring that effective vaccines can be developed and deployed when new infectious threats emerge.

Market Analysis

The global vaccine and immunization sector continues to develop because of the need for routine childhood vaccination, adult immunization, disease elimination programmes, pandemic preparedness, and the introduction of newer vaccines. The market is also being influenced by advances in vaccine platforms, improved manufacturing technologies, expanded immunization schedules, and efforts to increase access in underserved populations.

From a public-health perspective, the market opportunity is closely connected with the remaining immunization gap. WHO reported that 13.5 million children received no vaccination in 2025, while global DTP3 coverage reached 85%. HPV vaccination also remains an important growth area: global first-dose coverage among girls was 33% in 2025, compared with 17% in 2019. These figures indicate continued demand for vaccination programmes, new vaccine introductions, catch-up campaigns, and improved delivery systems.

The 2025–2030 period is particularly important for the vaccine sector because countries and international organizations are working toward the 2030 immunization targets. IA2030 targets include 90% coverage of essential vaccines and reducing the number of children completely missing vaccination. WHO's 2025 mid-term review also identified continuing gaps in routine coverage, equity, outbreak prevention, financing, and immunization-system resilience.

From 2027 onward, opportunities are expected across vaccine R&D, clinical research, manufacturing, cold-chain infrastructure, diagnostics, digital immunization systems, regulatory science, and population-level vaccination programmes. Vaccine supply and sustainability are also major priorities under IA2030, which specifically emphasizes reliable vaccine supply, affordability, forecasting, procurement, quality assurance, and emergency access.